Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1308
Article Code: 1308a
Date: March 23, 2009
Volume: 51
Pages: 21-22
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1308
Article Code: 1308a
Date: March 23, 2009
Volume: 51
Pages: 21-22
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)